Literature DB >> 7673103

Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence.

S S O'Malley1.   

Abstract

Numerous studies suggest that an integration of pharmacologic, psychological, and social therapies may lead to improved treatment outcomes for alcohol-dependent patients. This article discusses studies that show the benefits of treating opiate addiction and alcohol dependence with a combination of naltrexone and psychosocial therapies. It also reviews clinical strategies that may maximize the effectiveness of combining pharmacologic and psychosocial therapies for alcoholism. By matching patients with treatments and combining pharmacologic and psychosocial therapies, health care professionals may help alcohol-dependent patients avoid relapse and achieve sobriety. Determining the optimal amount of time an alcohol-dependent patient should be treated with naltrexone requires further study. The value of initiating naltrexone therapy during inpatient treatment should also be explored.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673103

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

Review 1.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 2.  Recommended drug treatment strategies for the alcoholic patient.

Authors:  A Schaffer; C A Naranjo
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 3.  Neuroscience: implications for treatment.

Authors:  I Petrakis; J Krystal
Journal:  Alcohol Health Res World       Date:  1997

4.  Morphine and ethanol pretreatment effects on expression and extinction of ethanol-induced conditioned place preference and aversion in mice.

Authors:  Christopher L Cunningham; Lee Bakner; Lindsey M Schuette; Emily A Young
Journal:  Psychopharmacology (Berl)       Date:  2020-09-26       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.